A case that could have big implications for patent law and the medical profession has reached the country's top court. MPR reports that lawyers for the Mayo Clinic on Wednesday morning will argue that a rival's blood-test patent goes too far. They say the patent also tries to cover the test's results. Prometheus sued Mayo for patent infringement after the clinic created its own blood test.

In their lawsuit the Justice Department and four whistleblowers claim Mayo billed the federal government for thousands of lab tests that were never done. The suit contends Mayo routinely billed Medicare and Medicaid for two sets of pathology tests, even though only one was conducted.

Steven VanNurden is currently the chair of Mayo Clinic Ventures. Under his guidance, the division has commercialized more than 2,000 technologies; was granted more than 1,200 patents and helped form more than 45 start-up companies. VanNurden will begin his new role as President and Chief Executive of the Fitzsimons Redevelopment Authority in late May.

The Mayo Clinic is among medical centers testing a device for patients whose high blood pressure does not respond to drugs. Medtronic's device uses a groundbreaking treatment to disrupt nerve signals that elevate blood pressure. But to qualify for the trial, patients must meet strict requirements that are challenging clinics and frustrating rejected patients.

Rochester-based Mayo Clinic and Minneapolis-based Fairview Health Services have signed a tentative agreement to transfer control of Red Wing Medical Center. Mayo Clinic Health System hopes to assume operations by July 1. The deal follows months of discussion.

A U.S. District Court has ruled competitor NuVasive must pay the Minnesota-based medical device maker more than $100 million in damages for infringing on three of its patents.